Wednesday , June 16 2021

▷ New BAG recommendation regarding vaccination with non-avalanche HPV vaccine



Document

Lucerne (ots) – The Federal Public Health Institute (FOPH) now recommends another vaccine for the prevention of HPV-related diseases. It will be available in vaccination programs at the beginning of 2019.

The Federal Public Health Institute (FOPH) now recommends another vaccine for the human papillomavirus (HPV) vaccine. A non-invasive HPV vaccine provides another option for the prevention of HPV-related diseases, such as cervical cancer, vaginal carcinoma and vulvar cancer.1

The high burden of HPV-related diseases in men and women

Human papillomavirus (HPV) infections are among the most common sexually transmitted infections. Contraction may be due to contact with an infected mucous membrane or during sexual intercourse. Most infections are treated without any consequences. However, certain types of HPV can lead to various types of cancer, such as cervix, anal, oral, pharyngeal, and penile penis.2 In Switzerland, about 250 women develop cervical cancer a year, and about 5,000 women develop a precursor for cervical cancer uterus. HPV cases of anal cancer diagnoses annually in about 160 women and men.3,4

Inoculation with a non-alaline medicine can prevent multiple HPV-related diseases

Prevention of HPV infection can provide a vaccine. Since 2007, HPV vaccines have been recommended by FOPH; at the beginning only for girls and women, from 2016, for boys and men aged 11 to 26 years.2

HPV vaccines available to date can protect against 2 or 4 types of HPV, making up about 70% of cervical cancer and about 50% of cervical cancer precursors. An irreplaceable HPV vaccine contains components of 9 HPV types. They cause about 90% of cervical cancer and about 80% of all cases of cervical cancer precursors.5,6 Thanks to the use of a non-valid HPV vaccine, it is possible to prevent a higher percentage of HPV-related illnesses in the future than before. 2

Recommendations for vaccination with a non-valid HPV vaccine are published in Bulletin 43 of the BAG and are available on the following line: http: //ots.ch/S5pEaJ

Letter of credit

1 Federal Public Health Institute (FOPH). HPV vaccination: BAG recommendations
and EKIF on new vaccine Gardasil 9® BAG Bulletin 43 of 22.
October 2018
2 Federal Public Health Institute; "HPV vaccine is effective and safe"
BAG Bulletin 3/18 January 15, 2018
3 Federal Public Health Office, HPV vaccination programs in Switzerland:
synthesis from 2007 to 2010 Bulletin BAG 2010; 43: 949-53;
4 Federal Public Health Institute; HPV vaccine: a recommendation for an additional vaccine
for boys and men aged 11 to 26 years. BAG Bulletin 10,
March 2, 2015.
5 Hartvig S et al. Papillomavirus Research 2015; (1) 90 - 100.
6 Hartvig S et al. Infectious agents and cancer 2017; 12: 19 

Full copies of study publications may be requested from MSD at the address below.

This information is intended exclusively for media professionals. MSD refers to the provisions on the advertising of pharmaceutical legislation, in particular on the prohibition of the publication of prescription drugs.

© 2018 MSD Merck Sharp and Dohme AG, Verftestrasse 4, 6005 Luzern. All Rights Reserved. Vacc-1274606-0000

About MSD

MSD is the world's leading biopharmaceutical company that has been researching life for over a century and has been developing drugs and vaccines for the most challenging diseases in the world. MSD is a registered name Merck & Co., Inc., Kenilworth, Nev. Jersey, USA. Our prescription drugs, vaccines, bioterapeutics and animal protection products provide innovative healthcare solutions in more than 140 countries. In addition, we are dealing with broad programs and partnerships to improve access to health care. Today MSD remains at the forefront of research on the prevention and treatment of diseases that endanger people and society around the world, including cancer, cardiovascular diseases, new animal diseases, Alzheimer's and infectious diseases, including HIV and Ebola. For more information, visit vvv.msd.com and follow us on Twitter.

MSD Human Medicine Switzerland

Switzerland is an important location for the company. 700 employees work at national and international offices. In Switzerland, the field of human medicine is responsible for the distribution of prescription and biopharmaceutical products in therapeutic areas of oncology, diabetes, cardiovascular, communicable diseases (including fungal infections, antibiotic resistance, HIV / AIDS and hepatitis C), immunology, women's health and vaccines for children, teens and adults.

MSD is active in clinical research in Switzerland, which produces medicines worldwide for clinical trials. Strengthening health literacy and healthcare economics is an additional concern for which MSD is committed locally. Likewise, MSD is dedicated to the location of Lucerne. In 2018, for the sixth consecutive year, the company received the Top Emploier certificate in Switzerland and for the third time the Top Emploier Europe Award.

More at: vvv.msd.ch

Follow us on Twitter, LinkedIn and YouTube.

© 2018 MSD Merck Sharp and Dohme AG, Verftestrasse 4, 6005 Luzern. All Rights Reserved.

Contact:

Liliane El Paso
Doc. Director of Policy and Communication
Phone. +41 58 618 34 24 / Mobile 079 235 58 90
[email protected]


Source link